Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial
Johann S. de Bono, Niven Mehra, Giorgio V. Scagliotti, et al.
The Lancet Oncology (2021) Vol. 22, Iss. 9, pp. 1250-1264
Closed Access | Times Cited: 228

Showing 1-25 of 228 citing articles:

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
Neeraj Agarwal, Arun Azad, Joan Carles, et al.
The Lancet (2023) Vol. 402, Iss. 10398, pp. 291-303
Closed Access | Times Cited: 281
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer
Noel W. Clarke, Andrew J. Armstrong, Antoine Thiery-Vuillemin, et al.
NEJM Evidence (2022) Vol. 1, Iss. 9
Closed Access | Times Cited: 268
Rucaparib or Physician’s Choice in Metastatic Prostate Cancer
Karim Fizazi, Josep M. Piulats, M. Neil Reaume, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 8, pp. 719-732
Open Access | Times Cited: 256
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
Kim N., Dana E. Rathkopf, Matthew R. Smith, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 18, pp. 3339-3351
Open Access | Times Cited: 206
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
Matthew R. Smith, Howard I. Scher, Shahneen Sandhu, et al.
The Lancet Oncology (2022) Vol. 23, Iss. 3, pp. 362-373
Open Access | Times Cited: 157
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
Yundong He, Weidong Xu, Yu‐Tian Xiao, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 120
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021
Silke Gillessen, Andrew J. Armstrong, G. Attard, et al.
European Urology (2022) Vol. 82, Iss. 1, pp. 115-141
Open Access | Times Cited: 104
Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial
K.N. Chi, Shahneen Sandhu, Matthew R. Smith, et al.
Annals of Oncology (2023) Vol. 34, Iss. 9, pp. 772-782
Open Access | Times Cited: 102
BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside
Stergios Boussios, Elie Rassy, Michele Moschetta, et al.
Cancers (2022) Vol. 14, Iss. 16, pp. 3888-3888
Open Access | Times Cited: 99
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
Karim Fizazi, Arun Azad, Nobuaki Matsubara, et al.
Nature Medicine (2023) Vol. 30, Iss. 1, pp. 257-264
Open Access | Times Cited: 59
CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer
Takuya Tsujino, Tomoaki Takai, Kunihiko Hinohara, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 52
New clinical trial design in precision medicine: discovery, development and direction
Xiao-Peng Duan, Bao‐Dong Qin, Xiao‐Dong Jiao, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 46
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study
Wassim Abida, David Campbell, Akash Patnaik, et al.
European Urology (2023) Vol. 84, Iss. 3, pp. 321-330
Open Access | Times Cited: 42
Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis
Jaleh Fallah, Jianjin Xu, Chana Weinstock, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 14, pp. 1687-1698
Closed Access | Times Cited: 35
Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes
David Olmos, David Lorente, Daniel Alameda, et al.
Annals of Oncology (2024) Vol. 35, Iss. 5, pp. 458-472
Open Access | Times Cited: 21
Development of PARP inhibitors in advanced prostate cancer
María T. Bourlon, Paola Valdez, Elena Castro
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 20
Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets
Alvina I. Khamidullina, Yaroslav E. Abramenko, Alexandra V. Bruter, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1263-1263
Open Access | Times Cited: 19
Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis
Syed Arsalan Ahmed Naqvi, Irbaz Bin Riaz, Arifa Bibi, et al.
European Urology (2025)
Closed Access | Times Cited: 1
BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations
Sidrah Shah, Rachelle Rachmat, Synthia Enyioma, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 23, pp. 12628-12628
Open Access | Times Cited: 75
The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment
Shuangying Li, Liangliang Wang, Yuanyuan Wang, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 60
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors
Timothy A. Yap, Aditya Bardia, Michael Dvorkin, et al.
JAMA Oncology (2022) Vol. 9, Iss. 1, pp. 40-40
Open Access | Times Cited: 58
Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS
Xiaojiang Tian, Lin Chen, Di Gai, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 49
French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Diagnosis and management of localised disease
Guillaume Ploussard, G. Fiard, É. Barret, et al.
Progrès en Urologie (2022) Vol. 32, Iss. 15, pp. 1275-1372
Closed Access | Times Cited: 37
PARP inhibitors in metastatic prostate cancer
Amy K. Taylor, David Kosoff, Hamid Emamekhoo, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 34
Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments
Thi Khanh Le, Quang Hieu Duong, Virginie Baylot, et al.
Cancers (2023) Vol. 15, Iss. 20, pp. 5047-5047
Open Access | Times Cited: 34
Page 1 - Next Page

Scroll to top